PRAX Director Granted 10,520 Stock Options at $44.04 鈥� Form 4

Q: Does the Form 4 show any open-market purchase or sale of PRAX shares?

No. The filing only reports an option grant; there were no purchases or sales of common stock.

Q: When will Gregory Norden鈥檚 PRAX options vest?

The options vest in 12 equal monthly tranches starting 26 Jun 2025 and are fully vested by 26 Jun 2026.

Q: What is the expiration date of the granted PRAX stock options?

The options expire on 26 Jun 2035, giving a 10-year exercise window.

Q: How many derivative securities does Gregory Norden own after this transaction?

Following the grant, Norden directly owns 10,520 PRAX stock options.

[Form 4] Praxis Precision Medicines, Inc. Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Praxis Precision Medicines, Inc. (PRAX) filed a Form 4 disclosing that director Gregory Norden received an option grant on 26 Jun 2025.

Derivative security issued: Non-qualified stock option covering 10,520 common shares with an exercise price of $44.04.
Vesting schedule: Vests in twelve equal monthly instalments beginning 26 Jun 2025, fully vested after one year.
Expiration: 26 Jun 2035 (10-year term).
Ownership impact: Following the grant, Norden beneficially owns 10,520 derivative securities (stock options) directly; no non-derivative share movement is reported.

The filing represents a routine equity incentive award to a board member and does not indicate any open-market purchase or sale of PRAX shares.

Positive

Equity alignment: Granting 10,520 options incentivises the director to focus on long-term share price appreciation, aligning board interests with shareholders.

Negative

None.

Insights

TL;DR: Routine director option grant; minimal immediate market impact, aligns incentives.

The Form 4 records a standard equity incentive: 10,520 options at $44.04 granted to director Gregory Norden. The grant vests over 12 months, ensuring the director maintains engagement through the next fiscal year. Because there is no share purchase or sale, cash flow and share count remain unchanged until the option is exercised. The strike price sets a benchmark; if PRAX trades below $44.04, the option is out-of-the-money, limiting dilution risk near term. Overall, this is a routine governance event with limited financial impact.

06/27/2025 - 04:55 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Norden Gregory

(Last)

(First)

(Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON

02110

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$44.04	06/26/2025		A		10,520		⁽¹⁾	06/26/2035	Common Stock	10,520	$0	10,520	D

Explanation of Responses:

1. The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 26, 2025.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Praxis Precision Medicines (PRAX) disclose in the latest Form 4?

PRAX disclosed that director Gregory Norden received a stock option for 10,520 shares on 26 Jun 2025 at a strike price of $44.04.

Does the Form 4 show any open-market purchase or sale of PRAX shares?

No. The filing only reports an option grant; there were no purchases or sales of common stock.

When will Gregory Norden鈥檚 PRAX options vest?

The options vest in 12 equal monthly tranches starting 26 Jun 2025 and are fully vested by 26 Jun 2026.

What is the expiration date of the granted PRAX stock options?

The options expire on 26 Jun 2035, giving a 10-year exercise window.

How many derivative securities does Gregory Norden own after this transaction?

Following the grant, Norden directly owns 10,520 PRAX stock options.

AG真人官方

[Form 4] Praxis Precision Medicines, Inc. Insider Trading Activity

Insights

FAQ

What did Praxis Precision Medicines (PRAX) disclose in the latest Form 4?

Does the Form 4 show any open-market purchase or sale of PRAX shares?

When will Gregory Norden鈥檚 PRAX options vest?

What is the expiration date of the granted PRAX stock options?

How many derivative securities does Gregory Norden own after this transaction?

NASDAQ:PRAX

PRAX Rankings

PRAX Latest News

PRAX Latest SEC Filings

PRAX Stock Data

AG真人官方

Trending News

[Form 4] Praxis Precision Medicines, Inc. Insider Trading Activity

Insights

Financial Analyst neutral

FAQ

What did Praxis Precision Medicines (PRAX) disclose in the latest Form 4?

Does the Form 4 show any open-market purchase or sale of PRAX shares?

When will Gregory Norden鈥檚 PRAX options vest?

What is the expiration date of the granted PRAX stock options?

How many derivative securities does Gregory Norden own after this transaction?

NASDAQ:PRAX

PRAX Rankings

PRAX Latest News

PRAX Latest SEC Filings

PRAX Stock Data